Alpine's Pipeline
We have a diverse pipeline of multi-targeted therapies in development for both autoimmune/inflammatory disease and immuno-oncology.
INFLAMMATORY DISEASES
ALPN-303
Dual B Cell Cytokine (BAFF/APRIL) Antagonist
Commmercial Rights:
ALPN-303 is a dual B cell cytokine antagonist being developed for multiple autoimmune and/or inflammatory diseases.
We reported data from the ongoing RUBY-1 study, a phase 1 study of ALPN-303 in healthy volunteers (NCT05034484) in September 2022. This study is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ALPN-303.
Partnered Programs
acazicolcept (ALPN-101)
Dual CD28/ICOS Antagonist
Partners:
Acazicolcept is a first-in-class dual inhibitor of the CD28 and ICOS T cell costimulatory pathways. The molecule is being developed for treatment of severe inflammatory diseases.
We are currently enrolling Synergy, a phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus (NCT04835441). This randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of acazicolcept.
Discovery Collaboration
Immunology
Next Generation TCR T-cell Therapies
For more information on our ongoing clinical trials please refer to the clinical trials portion of our website. For additional information please refer to our corporate filings, corporate presentations, and scientific publications.
Join us in the discovery and development of next-generation immunotherapies.
Current job openingsLearn more about Alpine
